X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Back to the future... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 10, 2006

    Pharma: Back to the future...

    Pharma stocks were at the receiving end in the recent meltdown witnessed in the Indian stockmarkets. We, however, continue to believe that FY07 will be the inflection point for pharma companies and will set the growth path for the future after the difficult past couple of years. With pharma companies slated to announce 1QFY07 results in July, we shall analyse major factors that are likely to influence the full year (FY07) performance.

    The growth drivers will be...

    The domestic market: The domestic pharma market is expected to grow in higher single digits in FY07, largely led by growth in the existing products of pharma companies. Most of the pharma majors with their strong product portfolio are expected to grow above the industry growth rate. In terms of new product launches, in-licensing products will play a critical growth in driving the topline. Besides, MNC pharma majors have begun to launch products from their parents' folio (case in point Glaxo and Pfizer), which have started contributing to the topline, albeit in a small way. However, investors should note that it would be a while before these products start making a significant contribution.

    Generics: As we have mentioned in earlier articles, the generics industry is expected to witness a revival with a large number of drugs going off patent in the US generics market. Besides Para III launches (drugs launched on Day 1 of patent expiry), there have been successes on the Para IV front as well (cases in point: Dr.Reddy's (for 'Simvastatin' and 'Proscar') and Ranbaxy (for 'Simvastatin 80 mg'). In addition, companies such as Cipla (which is partnering with global generic majors) will also stand to benefit immensely as the demand for bulk drugs starts picking pace on the back of a rise in ANDA approvals. These positive developments coupled with the contribution from the fast growing semi regulated markets of Russia, Africa, Asia and the Middle East are expected to significantly augment the revenue streams of pharma companies catering to the generics market.

    Acquisitions: FY06 was the year in which Indian pharma companies embarked on the inorganic route to acquire companies and establish a presence in the global markets. The efforts on this front will be reflected in the FY07 results of these companies. Notable examples include Dr. Reddy's acquisition of Betapharm (Germany), Ranbaxy's acquisition of Terapia (Romania) and Nicholas Piramal's acquisition of Avecia and Morpeth (both in the UK). Since most of these acquisitions were made in the latter half of FY06, the full year impact of the same will start flowing in from FY07 onwards. Besides, this year could possibly see more such acquisitions taking place as Ranbaxy, Dr. Reddy's, Wockhardt and Nicholas Piramal have clearly outlined inorganic growth as part of their strategy in the future.

    The margin story: While we expect margins as a whole to improve for companies under our coverage, the extent of improvement will depend upon the various business models adopted by these companies. For MNC pharma companies, the key will be improved product mix, reduced dependence on drugs under the DPCO control and cost efficiencies at the operating level. For domestic companies, the pricing pressure hampering margins will have to be offset by a continuous flow of products to the markets.

    However, concerns still remain...

    Pricing pressure: The pricing pressure in the US generics market has till now shown no real signs of abating. With the rise in patent expiries, the competition has also intensified, which is expected to pressurise the performance of generic companies. Even in FY07, with a rise in the number of patent expiries, prices could erode by as much as 90% on Day 1 itself (excluding the 180-day exclusivities). Therefore, besides a continuous flow of product launches, efforts made to diversify into other countries outside the US will be a positive move, which will enable companies to negate the impact of the highly competitive US market.

    Regulatory issues: Regulatory issues remain an area of concern both in India and abroad. In India, the threat of the new drug pricing policy to bring 354 essential drugs under price control looms like a dark cloud over the sector. Since, the policy has yet to be announced, it will be difficult to guage the exact impact of the same. While MNC pharma companies will stand to lose out, domestic pharma companies will also likely feel the pinch if this policy gets introduced. Abroad, the attractiveness of the German generics market could get slightly blunted with the new drug policy in the country making 30% price cuts mandatory for generic drugs.

    Investment in pharma stocks...
    While growth is visible in most of the pharma companies under our coverage, valuations will be the key factor to watch out for. After the carnage witnessed on the Indian bourses during the last week of May, we believe that valuations of certain pharma stocks look reasonable at the current juncture. As such, we advise investors to adopt a stock-specific investment strategy while investing in the sector.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Back to the future...". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 23, 2017 03:36 PM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS